

CENTRAL NERVOUS SYSTEM DISEASES



Boehringer Ingelheim welcomes collaborations with partners in **central nervous system diseases**, who share our passion for improving the health and wellbeing of animals, to help us find solutions to some of the biggest challenges in animal health today.

Pursuing Innovation

- Targeting high, unmet needs across a range of central nervous system diseases
- Leveraging synergies with human pharma to explore common pathological and clinical features
- Research focus on:
 - Cognitive dysfunction in dogs and cats
 - Anxiety in dogs, cats and horses.

Actively pursuing new partnerships in our areas of interest and open to a variety of partnership models to explore:

- Cognitive function assets with palliative or disease-modifying potential
- Non-sedating, rapid onset anxiety assets with non-scheduled dosing and low risk of disinhibition
- Novel models to demonstrate efficacy in the target species.

For more information visit:

<https://www.boehringer-ingelheim.com/partnering/working-together-in-ah/partnering-interests>

